Intuitive Surgical (NASDAQ:ISRG) executives said the company remains focused on global procedure growth, while acknowledging a recent deceleration in U.S. procedures and policy-related uncertainty affecting hospitals.
Speaking at a Wells Fargo conference, Executive Vice President, CFO and Enterpris
Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion.
Chief Financial Officer Thomas Dittrich, who recently returne
OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Speaking
Caterpillar (NYSE:CAT) Chairman and CEO Joe Creed said the company has started 2026 with strong demand across its three operating segments, supported by power-generation activity, construction equipment sales and improving orders in resource industries.
Speaking at a Wells Fargo Securities event, C
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat
Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion.
O’Ne
Medtronic (NYSE:MDT) executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief
McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.
The company said Precision Medicine Group would expand two areas it has id
In the past few months, investment banks have updated year end views on gold (“Au”) to US$4,500-$5,100/oz vs. the current price of ~$4,380. For example, Go
Digital identity verification and fraud prevention provider Socure has achieved a $5.2 billion valuation and buys following a strategic growth investment l
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
What Happened? Shares of payment processing company Shift4 Payments (NYSE:FOUR) jumped 4.6% in the morning session after Wells Fargo upgraded the company to ...
Stephen Weiss picks Dick's Sporting Goods, supported by Wells Fargo's upgrade. Jim Lebenthal's final trade is BlackRock, recommended by Evercore ISI's analyst upgrade. Shannon Saccocia recommends iShares U.S. Industrials ETF and Joseph M. Terranova mentions Charles Schwab breaking up.
